By otakuyassine3@gmail.com 
Pacer Advisors Inc. trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 3.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,168 shares of the medical research company’s stock after selling 1,778 shares during the period. Pacer Advisors Inc.’s holdings in Edwards Lifesciences were worth $3,492,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth $32,000. Avior Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at about $40,000. Finally, Roble Belko & Company Inc purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.
Insider Transactions at Edwards Lifesciences
In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock valued at $2,195,180 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.
Edwards Lifesciences Stock Up 2.8 %
Shares of NYSE:EW opened at $73.15 on Friday. The stock has a 50-day simple moving average of $72.40 and a 200-day simple moving average of $70.07. The stock has a market capitalization of $43.14 billion, a P/E ratio of 10.56, a PEG ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.
Analysts Set New Price Targets
EW has been the topic of several research reports. Piper Sandler lowered their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Citigroup raised their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Finally, Royal Bank of Canada lifted their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $79.19.
Read Our Latest Stock Report on EW
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
See Also
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edwards Lifesciences and related companies with MarketBeat.com’s FREE daily email newsletter.